Update date
31 Dec 2022
Shareable Research Card
Myovant Sciences Ltd. Return On Equity
This metric view shows Myovant Sciences Ltd. return on equity history from SEC company facts.
Use it to verify the latest reported value, compare nearby periods, and jump to a cross-company ranking when a curated insight exists.
- Context
- Latest reported period: Q4 2022
- Latest reported value
- 36%
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.
Return Loop
Why revisit this metric view
This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.
- Latest source-backed update
- Latest period end 31 Dec 2022
- Why come back
- Return after the next filing to verify whether this metric changed and how it compares with the ranking page.
- Current latest reported period: Q4 2022.
- Latest reported value on this page: 36%.
- Save this filer if you want to compare the next reported value with this history.
Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.
Latest update
Latest update for Return On Equity
Latest reported return on equity: 36%. Open the source-backed page to compare this metric with the newest filing-backed context.
Page type
Metric history
Latest period
Q4 2022
SEC-backed company facts were refreshed from filings filed on 26 Jan 2023.
Benchmark Context
How Return On Equity compares with peers
Myovant Sciences Ltd. is outside the visible top 120 companies for return on equity in the current sample.
Compared with
Compared with 120 companies reporting return on equity in %. This keeps the comparison on the same metric and unit family.
Why this is notable
This is about 0x the current sample midpoint. Return On Equity is down about 38% versus the comparable prior period.
- Visible rows currently span reported period ends from 30 Jun 2015 to 31 Mar 2026.
- Nearby companies in this sample: Wellgistics Health, Inc. and XCF Global, Inc..
- Peer rows use the latest valid value per company for this exact metric and compatible units.
Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.
Save this filer page
Create a free account to keep this page in your watchlists and return after a new SEC filing changes the record here.
Financial Metric Page
Myovant Sciences Ltd.: Return On Equity
Latest period: Q4 2022. Period end: 31 Dec 2022. Units: %. Frequency: quarterly and annual.
Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Metric Snapshot
- Latest value
- 36%
- Coverage range
- 30 Jun 2017 - 31 Dec 2022
- Fact rows
- 27
What This Metric Tells You
- Shows the reported level of return on equity over 30 Jun 2017 - 31 Dec 2022.
- Includes year-over-year change points to highlight acceleration or slowdown.
- Built from 27 SEC fact rows for this metric and issuer.
How To Read This Chart
- Start with the latest point, then compare it with the prior periods to see direction.
- Use quarterly sequence to compare like-for-like periods.
- Use YoY change bars to separate growth from contraction across matching periods.
Official SEC Source
Source: SEC Company Facts
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Reporting periods may differ by company.
Compare This Metric Across Companies
Compare latest available Return On Equity levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.
| Rank | Company | Latest value | Reported period | Next step |
|---|---|---|---|---|
| 1 | Wellgistics Health, Inc. (wgrx) | 141760% | Quarter - 31 Dec 2025 | Open Wellgistics Health, Inc. Return On Equity |
| 2 | XCF Global, Inc. (safx) | 77635% | Year - 31 Dec 2025 | Open XCF Global, Inc. Return On Equity |
| 3 | Cardiff Lexington Corp (cdix) | 49573% | Year - 31 Dec 2025 | Open Cardiff Lexington Corp Return On Equity |
| 4 | Bionik Laboratories Corp. | 46191% | Quarter - 31 Mar 2023 | Open Bionik Laboratories Corp. Return On Equity |
| 5 | Savara Inc (svra) | 43610% | Quarter - 31 Dec 2025 | Open Savara Inc Return On Equity |
| 6 | Athenex, Inc. | 25553% | Quarter - 31 Dec 2022 | Open Athenex, Inc. Return On Equity |
Metric Details
- Metric
- Return On Equity (ROE)
- Taxonomy
- ratio
- Units tracked
- %
- Frequency coverage
- quarterly and annual
- History range
- 30 Jun 2017 - 31 Dec 2022
- Facts on this page
- 27
- Description
- Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
- Metric-level SEC endpoint
- Open SEC company concept
Chart Context
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
Return On Equity, Quarterly (%)
Return On Equity, YoY Quarterly Change (%)
Return On Equity, Annual (%)
Return On Equity, YoY Annual Change (%)
Myovant Sciences Ltd. Quarterly Return On Equity (%)
| Period | Value | YoY Chg | Change % | Start Date | End Date |
|---|---|---|---|---|---|
| Q4 2022 | 36% | -22% | -38% | 01 Oct 2022 | 31 Dec 2022 |
| Q3 2022 | 40% | -28% | -41% | 01 Jul 2022 | 30 Sep 2022 |
| Q2 2022 | 37% | -55% | -60% | 01 Apr 2022 | 30 Jun 2022 |
| Q1 2022 | 49% | -58% | -54% | 01 Jan 2022 | 31 Mar 2022 |
| Q4 2021 | 58% | -76% | -57% | 01 Oct 2021 | 31 Dec 2021 |
| Q3 2021 | 68% | -136% | -67% | 01 Jul 2021 | 30 Sep 2021 |
| Q2 2021 | 93% | -277% | -75% | 01 Apr 2021 | 30 Jun 2021 |
| Q1 2021 | 106% | -1809% | -94% | 01 Jan 2021 | 31 Mar 2021 |
| Q4 2020 | 134% | +2423% | 01 Oct 2020 | 31 Dec 2020 | |
| Q3 2020 | 204% | +972% | 01 Jul 2020 | 30 Sep 2020 | |
| Q2 2020 | 370% | +916% | 01 Apr 2020 | 30 Jun 2020 | |
| Q1 2020 | 1916% | +2506% | 01 Jan 2020 | 31 Mar 2020 | |
| Q4 2019 | -2289% | -1838% | -407% | 01 Oct 2019 | 31 Dec 2019 |
| Q3 2019 | -768% | -426% | -124% | 01 Jul 2019 | 30 Sep 2019 |
| Q2 2019 | -546% | -302% | -124% | 01 Apr 2019 | 30 Jun 2019 |
| Q1 2019 | -590% | -441% | -296% | 01 Jan 2019 | 31 Mar 2019 |
| Q4 2018 | -451% | -360% | -397% | 01 Oct 2018 | 31 Dec 2018 |
| Q3 2018 | -343% | -289% | -538% | 01 Jul 2018 | 30 Sep 2018 |
| Q2 2018 | -244% | -168% | -220% | 01 Apr 2018 | 30 Jun 2018 |
| Q1 2018 | -149% | 01 Jan 2018 | 31 Mar 2018 | ||
| Q4 2017 | -91% | 01 Oct 2017 | 31 Dec 2017 | ||
| Q3 2017 | -54% | 01 Jul 2017 | 30 Sep 2017 | ||
| Q2 2017 | -76% | 01 Apr 2017 | 30 Jun 2017 |
Myovant Sciences Ltd. Annual Return On Equity (%)
| Period | Value | YoY Chg | Change % | Start Date | End Date |
|---|---|---|---|---|---|
| 2021 | 86% | -1605% | -95% | 01 Apr 2021 | 31 Mar 2022 |
| 2020 | 1691% | +2315% | 01 Apr 2020 | 31 Mar 2021 | |
| 2019 | -624% | -339% | -119% | 01 Apr 2019 | 31 Mar 2020 |
| 2018 | -284% | 01 Apr 2018 | 31 Mar 2019 |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.